1. Home >
  2. M&A >
  3. Divestiture >
  4. Sweden >
  5. Takara Bio Acquires Cellectis AB

M&A Deal Summary

Takara Bio Acquires Cellectis AB

On July 29, 2014, Takara Bio acquired life science company Cellectis AB from Cellectis

Acquisition Highlights
  • This is Takara Bio’s 1st transaction in the Life Science sector.
  • This is Takara Bio’s 1st transaction in Sweden.

M&A Deal Summary
Date 2014-07-29
Target Cellectis AB
Sector Life Science
Buyer(s) Takara Bio
Sellers(s) Cellectis
Deal Type Divestiture

Target

Cellectis AB

Gothenburg, Sweden
Cellectis AB is a biotechnology company focused on applications of human embryonic stem cell (HES) based products and technologies for the industry and the research community.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Takara Bio

Kusatsu, Japan
Category Company
Founded 2002
Sector Life Science
Employees1,779
Revenue 45.0B JPY (2025)
DESCRIPTION

Takara Bio is a biotechnology company that provides biotechnology research and development. Takara Bio active research and product development activities in the fields of gene and cell-based therapy and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Takara Bio was founded in 2002 and is based in Kusatsu, Japan.

DEAL STATS #
Overall 2 of 3
Sector: Life Science M&A 1 of 2
Type: Divestiture M&A Deals 2 of 2
Country: Sweden M&A 1 of 1
Year: 2014 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-07-01 Takara Bio USA Holdings

Mountain View, California, United States

Takara Bio USA Holdings, Inc. is a provider of kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function.

Buy $60M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-13 WaferGen Bio-systems

Fremont, California, United States

WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single-cell analysis and clinical research.

Buy $50M

Seller(S) 1

SELLER

Cellectis

Paris, France
Category Company
Founded 1999
Sector Life Science
Employees203
Revenue 50M EUR (2015)
DESCRIPTION

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). Cellectis was founded in 1999 and is based in Paris, France.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: Sweden M&A 1 of 1
Year: 2014 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-11-04 Cellartis AB

Gothenburg,, Sweden

Cellartis recognized as a premier provider of stem cell derived products and technologies. Company to bring to the market hepatocytes and cardiomyocytes derived from pluripotent stem cells for use as drug discovery tools and is widely.

Buy -
Mergr

Solution for

Product

Company

Legal